Omeros Stock Logs Best Session Ever After HC Wainwright Doubles Target On Novo Nordisk Deal; Retail Sees Big Upside The rally followed H.C. Wainwright’s price target hike to $20 on the back of a $2.1 billion licensing deal with Novo Nordisk for zaltenibart.
Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead Novo Nordisk’s $4.7B Akero deal boosts its metabolic health pipeline, targeting Eli Lilly’s lead in obesity and liver disease treatments
Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal Omeros stock jumps 164% as Novo Nordisk acquires global rights to zaltenibart, with potential milestones reaching $2.1 billion and tiered royalties.
Meet the 1.4% Yield Dividend Stock That Could Soar in 2026 The company is one of two major players in the rapidly growing obesity drug market. Yet, the stock has lost half its value.
Why Is Scholar Rock Stock Trading Lower On Monday? Scholar Rock stock falls as FDA issues Form 483 to Catalent; company to meet FDA, while apitegromab shows lean mass preservation in trial.
Why Are Regeneron And Scholar Rock Shares Falling On Monday? Regeneron and Scholar Rock’s submissions have been delayed or denied following an FDA inspection at the third-party fill-finish facility Catalent Indiana, owned by Novo Nordisk.
Down 44%, Should You Buy the Dip on Viking Therapeutics? The company is readying to take on pharma giants Novo Nordisk and Eli Lilly.
The Smartest Growth Stock to Buy With $100 Right Now This beaten-down drugmaker is well positioned to turn things around.
Drug Stocks Just Had Their Best Week in 2 Decades. Should You Invest? Now may be the time to invest in drug companies, as they just slipped the tariff noose.
3 Top Healthcare Stocks to Buy in October Healthcare stocks haven't been very popular this year. It could be a great time to buy some of the industry's leaders.
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO): A Prime Example of Affordable Growth Novo Nordisk exemplifies affordable growth, combining strong revenue and earnings expansion with a reasonable valuation and top-tier profitability.
Should You Buy Novo Nordisk Right Now? The fallen pharma giant could make a big comeback in 2026.
Bill Gates And PAHO Push To Make Weight-Loss Drugs Accessible In Low-Income Nations Bill Gates and PAHO are working to make weight-loss drugs like Wegovy and Mounjaro more affordable for low-income countries.
Eli Lilly Completes Phase 1 Study for Bimagrumab and Tirzepatide Amidst Strategic Pipeline Revisions Eli Lilly and Company (
NYSE: LLY ) has announced the completion of its Phase 1 bioavailability study for the combination of Bimagrumab and Tirzepatide on October 8, 2025, a foundational step in understanding the pharmacokinetic profile of this potential therapy. While this marks a technical advancement in drug development, the news
Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion Novo Nordisk to buy Akero Therapeutics for up to $5.2 billion, adding EFX, a late-stage MASH treatment candidate, to its metabolic disease portfolio.
What’s Driving The Super Rally In Akero Shares On Thursday Morning? Novo Nordisk is set to acquire the firm, and Akero’s shareholders will receive $54 per share in cash at closing in addition to a contingent value right.
Wegovy, Ozempic Maker Novo Nordisk Cuts Staff At Key US Production Sites Novo Nordisk has cut dozens of jobs at its Clayton, North Carolina site, part of a global restructuring as it faces slowing weight-loss drug sales.
Where Will LLY Be in 5 Years? After nearly two years of sideways price action, Eli Lilly stock could soar to new highs between now and 2030.
